Abstract. Hepatocellular carcinoma (HCC) is associated with some of the highest cancer-associated mortality rates. Histone deacetylase (HDAC) inhibitors anti-HCC activities have been shown to promote Snail-induced metastasis. In the present study, it was shown that BAY 87-2243, a hypoxia-inducible transcription factor-1α inhibitor, could enhance the anti-HCC effects of HDAC inhibitors, including trichostatin A and vorinostat. In addition, BAY 87-2243 plus HDAC inhibitors exhibited synergistic cytotoxicity and induced significant cell death in Hep3B cells. Additionally, BAY 87-2243 combined with HDAC inhibitors-treated Hep3B cells formed fewer and smaller colonies as compared with either the control or single agent-treated cells. Furthermore, glycogen synthase kinase-3β might be involved in the enhanced cell death induced by BAY 87-2243 plus HDAC inhibitors. The present data also indicated that BAY 87-2243 combined with HDAC inhibitors could suppress the migration of Hep3B cells, and BAY 87-2243 could reverse the HDAC inhibitor-induced Snail activation in Hep3B cells. In conclusion, BAY 87-2243 combined with HDAC inhibitors might be an attractive chemotherapy strategy for HCC therapy.
Introduction
Hepatocellular carcinoma (HCC), one of the most deadly cancers worldwide, accounts for the majority of primary liver cancer cases (1) . The overexpression of histone deacetylases (HDACs) plays an important role in almost all cancerous behaviors of HCC, including cancer initiation, progression and chemotherapy-resistance (2) . A number of HDAC inhibitors, such as vorinostat and trichostatin A, have been tested to treat HCC both in preclinical models and clinical trials (3) (4) (5) . HDAC inhibitors exert their anti-tumor activities by inducing cell cycle arrest, apoptosis, autophagy and differentiation (6) . Furthermore, combining HDAC inhibitors with other agents has been identified as a potential approach to overcoming chemotherapeutic resistance (7, 8) .
Hypoxia activates genetic programs that facilitate HCC cell metastasis, proliferation, as well as chemotherapy and radiotherapy-resistance (9) . Hypoxia-inducible transcription factor (HIF) is activated in HCC cells under hypoxic conditions, leading to angiogenesis and poor prognosis (10) . BAY 87-2243 inhibits HIF-1α and HIF-2α protein accumulation under hypoxia, and BAY 87-2243 also suppresses the activity of mitochondrial complex I in non-small cell lung cancer (11) . Furthermore, BAY 87-2243 significantly reduces tumor growth in BRAF mutant melanoma cancer cells by targeting mitochondrial complex I (12) . BAY 87-2243 induces mitochondrial permeability transition pore opening, stimulates autophagosome formation and leads to the activation of necroptotic/ferroptotic cell death in melanoma cells (13) . In addition, the reduction of tumor hypoxia by application of BAY-87-2243 before the beginning of fractionated radiotherapy can improve local tumor control (14) .
The activation of HDAC and hypoxia are associated with cancer initiation, progression and chemo-resistance in HCC cells (9, 10 Cell proliferation assays. Hep3B cells were seeded into 96-well plates at a density of 4x10 3 per well and were allowed to grow overnight at 37˚C. The cells were incubated with BAY 87-2243 (2 or 4 µM) and/or HDAC inhibitors (0.2-4 µM) for 72 h at 37˚C. Cell proliferation was detected by the SRB assay, as previously described (9) . Briefly, cells were fixed with 10% trichoroacetic acid solution at 4˚C overnight. Subsequent to washing, 0.4% SRB solution (100 µl per well; Sigma-Aldrich) was added into each well. After 20 min staining at room temperature, wells were rinsed with 1% acetic acid to remove unbound dye and then left to air dry. Subsequently, 100 µl Tris-base lye (10 mM; NeoFROXX GmbH) was added, followed by 10-min oscillation. The absorbance was then recorded at 515 nm using a multiscan spectrum.
Colony formation assay. Hep3B cells were seeded onto 6-well plates at a density of 1,000 cells per well. After 14 days, cells were stained with 0.1% crystal violet solution for 30 min at 4˚C and the colonies were imaged by a camera.
Detection of cell death. Hep3B cells were seeded into 6 well plates and incubated with BAY 87-2243 (10 µM; higher than the SRB assay using 96 well plates) and/or and/or HDAC inhibitors (0.25-2 µM), and PI staining was then used to detect cell death, as previously described (9) . Sub-G1 analysis following PI staining was used to detect apoptosis. Cells were harvested, washed with PBS three times and fixed with pre-cooled 70% ethanol at -20˚C overnight. Cells were washed and resuspended in 500 µl PBS containing 50 µg/ml RNase at 37˚C for 30 min. The cells were then stained with 5 µg PI at room temperature for 30 min. For each sample, 2x10 4 cells were collected and analyzed using a FACS-Calibur cytometer and the data were analyzed using Cellquest Software (version 6.0; BD Biosciences).
Western blot analysis. Western blot analysis was performed as previously described (9) . Proteins were extracted with lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, 0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid, 0.5% deoxycholic acid, 1% NP-40, 2.0 µg/ml aprotinin, 1 mM phenylmethylsulfonylfluoride and 0.02% sodium azide (Beyotime Institute of Biotechnology). The lysates were centrifuged at 10,000 x g for 30 min at 4˚C, then the concentrations of protein were determined by the BCA method using Enhanced BCA Protein Assay kit (Beyotime Institute of Biotechnology). Total proteins (40 µg/lane) were fractionated on 8-15% Tris-glycine gels, and then they were transferred to polyvinylidene fluoride membrane, blocked with 5% (w/v) Difco Skim milk (cat. no. 232100; BD Biosciences) in PBS at room temperature for 1 h and probed with the primary antibodies at 4˚C overnight. The proteins were incubated and visualized with horseradish peroxidase-conjugated goat anti-mouse (cat. no. GAM007) and anti-rabbit (cat. no. GAM007) IgG secondary antibodies (MultiSciences) at a dilution of 1:5,000 for 1 h at room temperature. Finally, proteins were visualized using the enhanced chemiluminescence detection system (PerkinElmer). Anti-poly (ADP-ribose) polymerase (PARP; cat. no. sc-7150; 1:1,000), anti-AKT (cat. no. sc-135829; 1:500), anti-phospho-AKT (Ser-473; cat. no. sc-7985; 1:500) and anti-GAPDH (cat. no. sc-25778; 1:1,000) antibodies were obtained from Santa Cruz Biotechnology, Inc. Anti-phospho-glycogen synthase kinase (GSK)-3β (Ser-9; cat. no. 5558S; 1:500) and anti-snail antibodies (cat. no. 3879S; 1:1,000) were purchased from Cell Signaling Technology, Inc. Anti-GSK3β antibody (cat. no. 610202; 1:1,000) was obtained from BD Biosciences.
Wound healing assay. Hep3B cells were seeded in 24-well plates and cultured until they reached 90% confluency. Confluent monolayer cells were gently scratched with a sterile pipette tip and then washed three times with PBS to clear cell debris and suspended cells. Fresh serum-free medium was added, and the cells were allowed to close the wound for 24 h under normal conditions at 37˚C. Images of the wound in the same relative position were captured with a computer-assisted microscope (model, CKX41SF; Olympus Corporation).
Statistical analysis.
One-way analysis of variance followed by Tukey post hoc test was used to examine the significance of differences among groups. The results were presented as the mean ± standard deviation from three independent experiments and P<0.05 was used to indicate a statistically significant difference.
Results

BAY 87-2243 enhances the HDAC inhibitor-induced antiproliferative effect of Hep3B cells.
First, the morphological changes induced by the combined treatment of BAY 87-2243 and HDAC inhibitors was detected in Hep3B cells. Fig. 1A showed that a very large proportion of Hep3B cells treated with BAY 87-2243 plus HDAC inhibitors (trichostatin A or vorinostat) had dislodged from the dishes whereas the remaining adherent cells showed loss of adhesion, shrinkage and rounding, which are typical morphological changes associated with apoptosis (15) . Furthermore, the results presented in Fig. 1B showed that BAY 87-2243 combined with HDAC inhibitors (trichostatin A or vorinostat) significantly decreased the proliferation ability of Hep3B cells following incubation for 72 h, as compared with single agent-treatment. To further confirm the enhanced antiproliferative effect of the combined treatment with BAY 87-2243 and HDAC inhibitors, whether the combination might inhibit colony formation in Hep3B cells or not, was determined next. It was found that BAY 87-2243 combined with HDAC inhibitors-treated Hep3B cells formed fewer and smaller colonies as compared with either the control or single agent-groups (P<0.0001; Fig. 2A and B) . These results confirmed that BAY 87-2243 enhanced the HDAC inhibitor-induced antiproliferative effect in Hep3B cells. Fig. 3A; upper panel) . Similarly, the combination treatment of BAY 87-2243 and vorinostat resulted in an increased apoptotic rate, as compared with single agent groups ( Fig. 3A; lower panel) . Therefore, BAY 87-2243 enhanced HDAC inhibitor-induced cell death in Hep3B cells (P<0.0001; Fig. 3B ). Furthermore, the BAY 87-2243 plus HDAC inhibitor-induced enhanced apoptosis was accompanied by higher expression of the cleaved PARP, in Hep3B cells (Fig. 4A) .
BAY 87-2243 combined with HDAC inhibitors induces cell death via GSK3β activation.
The AKT/GSK-3β/Snail pathway has been shown to be involved in HCC metastasis by inducing epithelial-mesenchymal transition (EMT) (16, 17) . The transcription factor Snail, controls EMT by repressing the expressions of E-cadherin and other epithelial genes, and GSK-3β phosphorylates Snail inducing its degradation (18) . The present data indicated that BAY 87-2243 plus HDAC inhibitors could markedly inhibit AKT, Snail and activate GSK-3β by suppressing phosphorylated GSK-3β (Ser-9; Fig. 4A ). Furthermore, it was found that GSK-3β inhibitor CHIR-99021 could partially reverse the cell death induced by BAY 87-2243 plus HDAC inhibitors ( Fig. 4B; P<0.001) . Thus, the potential ability of BAY 87-2243 plus HDAC inhibitors to inhibit the AKT/GSK-3β/Snail pathway makes it an attractive chemotherapy strategy to hinder HCC metastasis, but this needs to be investigated further. 
Discussion
HCC is a metabolically heterogeneous cancer, and the use of glucose by HCC cells can influence their tumorigenicity (19) . Therefore, increased glucose metabolism is important for the growth of HCC cells (20) . In addition, the suppression of HIF-1α could be activated by hypoxia-independent mechanisms such as the PI3K/AKT/mTOR signaling pathway (21) . In the present study, BAY 87-2243 as a HIF-1α inhibitor could decrease p-AKT (ser-473), indicating that HIF-1α suppression could also affect PI3K/AKT/mTOR signaling pathway. Furthermore, the present data also indicated that BAY 87-2243 plus HDAC inhibitors could suppress PI3K/AKT/mTOR signaling. In addition, the inactivation of GSK-3β plays an important role in mediating the improved glucose metabolism, and GSK-3β (Ser-9) phosphorylation reduces the activity of GSK-3β (22, 23) . In the present study, it was shown that BAY 87-2243 plus HDAC inhibitors could activate GSK-3β by suppressing phosphorylated GSK-3β (Ser-9). In addition, GSK-3β inhibitor CHIR-99021 successfully reversed the cell death induced by BAY 87-2243 plus HDAC inhibitors. These data indicated that BAY 87-2243 plus HDAC inhibitors might suppress glucose metabolism by activating GSK-3β in HCC cells.
The majority of HCC patients are diagnosed in advanced stages of the disease, and the poor survival in patients with HCC can be largely attributed to rapid intrahepatic recurrence due to cancer metastases (24) . HDAC inhibitors, including trichostatin A and vorinostat, induce cell death but simultaneously augment cell migration and metastasis to ruin therapeutic efficacy via activating protein kinase C signaling (25) . Furthermore, HDAC inhibitors are able to promote the expression of Snail, and trigger Snail-induced EMT which is critical for HDAC inhibitors-initiated invasion and metastasis (26) . The findings of the present study highlighted that BAY 87-2243 could reverse the HDAC inhibitor-induced activation of Snail in HCC cells. Furthermore, the present data showed that BAY 87-2243 plus HDAC inhibitor could significantly suppress the migration of HCC cells, indicating that combining BAY 87-2243 with HDAC inhibitors appears to be an attractive option for the patients with metastatic HCC. However, further research is required to elucidate the anti-metastatic activity of BAY 87-2243 plus HDAC inhibitors in HCC.
In conclusion, the present data provided, to the best of our knowledge, the first evidence that BAY 87-2243 could enhance the anti-HCC effect of HDAC inhibitors through the AKT/GSK-3β/Snail signaling pathway (Fig. 6) . It was also shown that BAY 87-2243 plus Vorinostat could inhibit the migration of Hep3B cells. BAY 87-2243 plus HDAC inhibitors might be an attractive chemotherapy strategy for HCC therapy.
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